Literature DB >> 20853437

Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination.

Emily P Harrington1, Chao Zhao, Stephen P J Fancy, Sovann Kaing, Robin J M Franklin, David H Rowitch.   

Abstract

OBJECTIVE: Repair of myelin injury in multiple sclerosis may fail, resulting in chronic demyelination, axonal loss, and disease progression. As cellular pathways regulated by phosphatase and tensin homologue deleted on chromosome 10 (PTEN; eg, phosphatidylinositol-3-kinase [PI-3K]) have been reported to enhance axon regeneration and oligodendrocyte maturation, we investigated potentially beneficial effects of Pten loss of function in the oligodendrocyte lineage on remyelination.
METHODS: We characterized oligodendrocyte numbers and myelin sheath thickness in mice with conditional inactivation of Pten in oligodendrocytes, Olig2-cre, Pten(fl/fl) mice. Using a model of central nervous system demyelination, lysolecithin injection into the spinal cord white matter, we performed short- and long-term lesioning experiments and quantified oligodendrocyte maturation and myelin sheath thickness in remyelinating lesions.
RESULTS: During development, we observed dramatic hypermyelination in the corpus callosum and spinal cord. Following white matter injury, however, there was no detectable improvement in remyelination. Moreover, we observed progressive myelin sheath abnormalities and massive axon degeneration in the fasciculus gracilis of mutant animals, as indicated by ultrastructure and expression of SMI-32, amyloid precursor protein, and caspase 6.
INTERPRETATION: These studies indicate adverse effects of chronic Pten inactivation (and by extension, activation PI-3K signaling) on myelinating oligodendrocytes and their axonal targets. We conclude that PTEN function in oligodendrocytes is required to regulate myelin thickness and preserve axon integrity. In contrast, PTEN is dispensable during myelin repair, and its inactivation confers no detectable benefit.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20853437      PMCID: PMC2966537          DOI: 10.1002/ana.22090

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  40 in total

1.  Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57BL/6 mice.

Authors:  K-A Irvine; W F Blakemore
Journal:  J Neuroimmunol       Date:  2006-04-19       Impact factor: 3.478

2.  Bace1 modulates myelination in the central and peripheral nervous system.

Authors:  Xiangyou Hu; Caitlin W Hicks; Wanxia He; Philip Wong; Wendy B Macklin; Bruce D Trapp; Riqiang Yan
Journal:  Nat Neurosci       Date:  2006-11-12       Impact factor: 24.884

3.  Involvement of the Olig2 transcription factor in cholinergic neuron development of the basal forebrain.

Authors:  Miki Furusho; Katsuhiko Ono; Hirohide Takebayashi; Noritaka Masahira; Tetsushi Kagawa; Kazuyo Ikeda; Kazuhiro Ikenaka
Journal:  Dev Biol       Date:  2006-03-13       Impact factor: 3.582

4.  Remyelination is extensive in a subset of multiple sclerosis patients.

Authors:  Peter Patrikios; Christine Stadelmann; Alexandra Kutzelnigg; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Wolfgang Brück; Claudia Lucchinetti; Hans Lassmann
Journal:  Brain       Date:  2006-08-18       Impact factor: 13.501

5.  Neuregulin-1 type III determines the ensheathment fate of axons.

Authors:  Carla Taveggia; George Zanazzi; Ashley Petrylak; Hiroko Yano; Jack Rosenbluth; Steven Einheber; Xiaorong Xu; Raymond M Esper; Jeffrey A Loeb; Peter Shrager; Moses V Chao; Douglas L Falls; Lorna Role; James L Salzer
Journal:  Neuron       Date:  2005-09-01       Impact factor: 17.173

Review 6.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors:  Kenneth R Carson; Daniele Focosi; Eugene O Major; Mario Petrini; Elizabeth A Richey; Dennis P West; Charles L Bennett
Journal:  Lancet Oncol       Date:  2009-08       Impact factor: 41.316

7.  Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries.

Authors:  Isaias Glezer; Amelie Lapointe; Serge Rivest
Journal:  FASEB J       Date:  2006-02-07       Impact factor: 5.191

8.  Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression.

Authors:  Mark R Kotter; Chao Zhao; Nico van Rooijen; Robin J M Franklin
Journal:  Neurobiol Dis       Date:  2005-02       Impact factor: 5.996

9.  Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS.

Authors:  Stephen P J Fancy; Chao Zhao; Robin J M Franklin
Journal:  Mol Cell Neurosci       Date:  2004-11       Impact factor: 4.314

10.  Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation.

Authors:  Mark R Kotter; Wen-Wu Li; Chao Zhao; Robin J M Franklin
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

View more
  88 in total

1.  Erk1/2 MAPK and mTOR signaling sequentially regulates progression through distinct stages of oligodendrocyte differentiation.

Authors:  Hebe M Guardiola-Diaz; Akihiro Ishii; Rashmi Bansal
Journal:  Glia       Date:  2011-12-05       Impact factor: 7.452

2.  Inhibitors of myelination: ECM changes, CSPGs and PTPs.

Authors:  Danielle E Harlow; Wendy B Macklin
Journal:  Exp Neurol       Date:  2013-11-04       Impact factor: 5.330

3.  Signaling by FGF Receptor 2, Not FGF Receptor 1, Regulates Myelin Thickness through Activation of ERK1/2-MAPK, Which Promotes mTORC1 Activity in an Akt-Independent Manner.

Authors:  Miki Furusho; Akihiro Ishii; Rashmi Bansal
Journal:  J Neurosci       Date:  2017-02-13       Impact factor: 6.167

4.  Caspase-6 Undergoes a Distinct Helix-Strand Interconversion upon Substrate Binding.

Authors:  Kevin B Dagbay; Nicolas Bolik-Coulon; Sergey N Savinov; Jeanne A Hardy
Journal:  J Biol Chem       Date:  2017-02-02       Impact factor: 5.157

5.  Apcdd1 stimulates oligodendrocyte differentiation after white matter injury.

Authors:  Hyun Kyoung Lee; Dylan Laug; Wenyi Zhu; Jay M Patel; Kevin Ung; Benjamin R Arenkiel; Stephen P J Fancy; Carrie Mohila; Benjamin Deneen
Journal:  Glia       Date:  2015-05-06       Impact factor: 7.452

6.  PTEN inhibitor bisperoxovanadium protects oligodendrocytes and myelin and prevents neuronal atrophy in adult rats following cervical hemicontusive spinal cord injury.

Authors:  Chandler L Walker; Xiao-Ming Xu
Journal:  Neurosci Lett       Date:  2014-02-26       Impact factor: 3.046

7.  R-Ras1 and R-Ras2 Are Essential for Oligodendrocyte Differentiation and Survival for Correct Myelination in the Central Nervous System.

Authors:  Miriam Sanz-Rodriguez; Agnès Gruart; Juan Escudero-Ramirez; Fernando de Castro; José María Delgado-García; Francisco Wandosell; Beatriz Cubelos
Journal:  J Neurosci       Date:  2018-05-02       Impact factor: 6.167

Review 8.  Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder.

Authors:  Amanda K Tilot; Thomas W Frazier; Charis Eng
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 9.  Intracellular signaling pathway regulation of myelination and remyelination in the CNS.

Authors:  Jenna M Gaesser; Sharyl L Fyffe-Maricich
Journal:  Exp Neurol       Date:  2016-03-05       Impact factor: 5.330

Review 10.  Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis.

Authors:  Alexandre Vallée; Jean-Noël Vallée; Rémy Guillevin; Yves Lecarpentier
Journal:  Cell Mol Neurobiol       Date:  2017-09-13       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.